精鍛科技(300258.SZ):擬合資設立江蘇太平洋關節電驅科技
格隆匯3月17日丨精鍛科技(300258.SZ)公佈,公司爲緊抓機器人行業快速發展的戰略機遇,加快在人形機器人關節與絲槓及其電機驅動模組核心部件領域的研發與產業化進程,搶佔產業鏈關鍵環節,擬與天津愛碼信自動化技術有限公司(簡稱“天津愛碼信”)共同出資設立“江蘇太平洋關節電驅科技有限公司”(暫定名,最終以公司登記機關覈準的名稱爲準,以下簡稱“合資公司”)。合資公司註冊資本爲人民幣1億元,其中公司認繳9,000萬元,佔合資公司90%的股權,天津愛碼信認繳1,000萬元,佔合資公司10%的股權。此次合作將充分發揮雙方優勢,助力公司在機器人核心零部件領域實現技術突破與市場拓展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.